Table 2 Treatment characteristics
No. (%) | |
|---|---|
Started treatment with dose reduction, n (%) | |
Only gemcitabine | 1 (0.5) |
Only nab-Paclitaxel | 41 (19.5) |
Both | 26 (12.4) |
Dose reduction during treatment, n (%) | |
Nab-Paclitaxel | 91 (43.3) |
Gemcitabine | 75 (35.7) |
Either of the two drugs | 96 (45.7) |
Received ≤30 days of treatment, n (%) | 34 (16.5) |
Reasons for treatment discontinuationa, n (%) | |
Progression | 134 (69.8) |
Toxicity | 33 (17.2) |
Death | 24 (12.5) |
Patient’s request | 7 (3.6) |